Development of NLRP3 Inflammasome Inhibitors for Neuroinflammatory Conditions
A novel small molecule drug that blocks the ATPase activity of the nucleotide-binding domain for the inhibition of inflammasome pathways
Published: 28th March 2022

IP Status
- Patent application submitted